Rhythm Pharmaceuticals (RYTM) Interest Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Interest Expenses data on file, last reported at $4.6 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 15.27% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $19.8 million, a 2.26% decrease from a year earlier, with the FY2025 full-year figure at $381.2 million, up 17.1% from the prior year.
• Interest Expenses for Q1 2026 stood at $4.6 million, down from $4.6 million in the prior quarter.
• Over the last five years, Interest Expenses for RYTM reached as high as $5.9 million in Q3 2024 and fell as low as $2.6 million in Q2 2022.
• Historically, Interest Expenses has averaged $4.2 million across 5 years, with a median of $4.6 million in 2026.
• On a YoY basis, Interest Expenses climbed as much as 229.26% in 2022 and fell as far as 23.76% in 2022.
• Year by year, Interest Expenses stood at $3.0 million in 2022, then surged by 51.11% to $4.6 million in 2023, then increased by 19.71% to $5.4 million in 2024, then decreased by 15.27% to $4.6 million in 2025, then retreated by 0.69% to $4.6 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $4.6 million in Q1 2026, $4.6 million in Q4 2025, and $4.7 million in Q3 2025.